TY - JOUR T1 - Data-Driven Real-Time Strategic Placement of Mobile Vaccine Distribution Sites JF - medRxiv DO - 10.1101/2021.12.15.21267736 SP - 2021.12.15.21267736 AU - Zakaria Mehrab AU - Mandy L. Wilson AU - Serina Chang AU - Galen Harrison AU - Bryan Lewis AU - Alex Telionis AU - Justin Crow AU - Dennis Kim AU - Scott Spillmann AU - Kate Peters AU - Jure Leskovec AU - Madhav V. Marathe Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/19/2021.12.15.21267736.abstract N2 - The deployment of vaccines across the US provides significant defense against serious illness and death from COVID-19. Over 70% of vaccine-eligible Americans are at least partially vaccinated, but there are pockets of the population that are under-vaccinated, such as in rural areas and some demographic groups (e.g. age, race, ethnicity). These unvaccinated pockets are extremely susceptible to the Delta variant, exacerbating the healthcare crisis and increasing the risk of new variants. In this paper, we describe a data-driven model that provides real-time support to Virginia public health officials by recommending mobile vaccination site placement in order to target under-vaccinated populations. Our strategy uses fine-grained mobility data, along with US Census and vaccination uptake data, to identify locations that are most likely to be visited by unvaccinated individuals. We further extend our model to choose locations that maximize vaccine uptake among hesitant groups. We show that the top recommended sites vary substantially across some demographics, demonstrating the value of developing customized recommendation models that integrate fine-grained, heterogeneous data sources. In addition, we used a statistically equivalent Synthetic Population to study the effect of combined demographics (eg, people of a particular race and age), which is not possible using US Census data alone. We validate our recommendations by analyzing the success rates of deployed vaccine sites, and show that sites placed closer to our recommended areas administered higher numbers of doses. Our model is the first of its kind to consider evolving mobility patterns in real-time for suggesting placement strategies customized for different targeted demographic groups. Our results will be presented at IAAI-22, but given the critical nature of the pandemic, we offer this extended version of that paper for more timely consideration of our approach and to cover additional findings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by the National Institutes of Health (NIH) Grant R01GM109718, VDH Grant PV-BII VDH COVID-19 Modeling Program VDH-21-501-0135, NSF Grant No.: OAC-1916805, NSF Expeditions in Computing Grant CCF-1918656, CCF-1917819, NSF RAPID CNS-2028004, NSF RAPID OAC-2027541, US Centers for Disease Control and Prevention 75D30119C05935, DTRA subcontract/ARA S-D00189-15-TO-01-UVA. We also gratefully acknowledge the support of DARPA under Nos. HR00112190039 (TAMI), N660011924033 (MCS); ARO under Nos. W911NF-16-1-0342 (MURI), W911NF-16-1-0171 (DURIP); NSF under Nos. OAC-1835598 (CINES), OAC-1934578 (HDR), CCF-1918940 (Expeditions), IIS-2030477 (RAPID), NIH under No. R56LM013365; Stanford Data Science Initiative, Wu Tsai Neurosciences Institute, Chan Zuckerberg Biohub, Amazon, JPMorgan Chase, Docomo, Hitachi, Intel, KDDI, Toshiba, NEC, and UnitedHealth Group. J.L. is a Chan Zuckerberg Biohub investigator.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board for Social and Behavioral Sciences of the University of Virginia gave ethical approval for this work on 2021-10-15 under Protocol #4206, titled "Biocomplexity Institute COVID-19 Response: Surveillance, Modeling, and Operational Support"I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -